New Research Looks at The Role of Phentermine/Topiramate Extended-release in the Treatment of Obesity and Obesity-related Adverse Health Consequences

Share Article

US Endocrinology, the peer-reviewed journal, publish cutting-edge article by James R Gavin III on The Role of Phentermine/Topiramate Extended-release in the Treatment of Obesity and Obesity-related Adverse Health Consequences

News Image
Long-term pharmacologic strategies that may be used in conjunction with lifestyle changes to combat the obesity epidemic have, until recently, been an unmet clinical need.

US Endocrinology, the peer-reviewed journal, publish cutting-edge article by James R Gavin III on The Role of Phentermine/Topiramate Extended-release in the Treatment of Obesity and Obesity-related Adverse Health Consequences.

Long-term pharmacologic strategies that may be used in conjunction with lifestyle changes to combat the obesity epidemic have, until recently, been an unmet clinical need. In 2012, the US Food and Drug Administration (FDA) approved two new drugs for chronic weight management in obese adults in conjunction with a reduced-calorie diet and increased physical activity: phentermine/topiramate extended-release (PHEN/TPM ER) and lorcaserin. The efficacy and safety of PHEN/TPM ER has been studied in clinical trials. PHEN/TPM ER had a substantial impact on weight loss with the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) target of 10 % weight loss from baseline being achieved in almost half of patients receiving PHEN/TPM ER 15/92. Furthermore, PHEN/TPM ER was associated with improvement in obesityrelated adverse health consequences, including hyperglycemia, dyslipidemia, and hypertension, and a reduction in the rate of progression to type 2 diabetes. This clinical evidence supports PHEN/TPM ER as an efficacious, well-tolerated anti-obesity agent that may also have a significant impact on obesity-related adverse health consequences.

To continue reading this peer-reviewed article in full for free please go to:http://www.touchendocrinology.com/articles/role-phenterminetopiramate-extended-release-treatment-obesity-and-obesity-related-adverse-h

NOTE TO EDITORS
touchENDOCRINOLOGY (a division of Touch Medical Media) provides independent, cutting-edge, peer-reviewed content from world renowned physicians, designed to lead the debate on health and to engage, inform, and support physicians in improving patient outcomes globally.

touchENDOCRINOLOGY.com provides an international platform for peer-reviewed content from industry-leading journals alongside other carefully selected sources and aims to support physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity within the field of diabetes.

Our portfolio of peer-reviewed journals, European Endocrinology and US Endocrinology comprise of concise review articles which are designed to keep busy physicians up-to-date with the latest developments in their field and serve as a key reference resource for the international diabetes community.

http://www.touchendocrinology.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Barney Kent
@touchENDOCRINE
since: 10/2012
Follow >
Touch Medical Media

Visit website